Cassava Sciences Corporate Update on November 25th: Insights from Quantisnow
Cassava Sciences is gearing up for an exciting event! On Monday, November 25th at 8:00 a.m. Eastern Time, the clinical-stage biotechnology company based in Austin, Texas, will be holding a conference call and webcast. If you’re interested in learning more about their novel treatment for Alzheimer’s disease, you can tune in by visiting https://lifescievents.com/event/cassava/.
During this event, Cassava Sciences will provide updates and insights into their ongoing work with Simufilam, an oral, small molecule drug candidate currently undergoing Phase 3 clinical trials for Alzheimer’s disease treatment. This investigational drug targets the filamin A protein in hopes of making a positive impact on neurodegenerative diseases.
If you miss the live event, don’t worry! A replay of the webcast will be available on the Company Presentations page of the Cassava Sciences website for 90 days after the initial broadcast.
Cassava Sciences is dedicated to their mission of detecting and treating neurodegenerative diseases, particularly Alzheimer’s disease. To learn more about their work and upcoming events, visit https://www.CassavaSciences.com.
In other news, Freda Nassif has been appointed as the Chief Commercial Officer of Cassava Sciences. This significant development will play a crucial role in their commercial readiness strategy as they prepare for major milestones by the end of 2024.
Stay tuned for the release of top-line results from their Phase 3 trial for Simufilam, as the company aims to make a difference in the field of Alzheimer’s disease treatment. Exciting times lie ahead for Cassava Sciences and their innovative approach to tackling this challenging condition.
